Hypoxic Pulmonary Vasoconstriction Pilot Study
Pilot Study for Perfusion Heterogeneity: a Mechanistic Image-Based Emphysema Phenotype
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be between the ages of 30 and 60.
- Must be currently smoking at least 1/2 pack/day (confirmed with cotinine level).
- Must have pulmonary function test (PFT) results that meet the following:
- Forced Expiratory Volume at one second (FEV1)/Forced Vital Capacity (FVC) > 70%
- Forced Expiratory Flow at 25-75% (FEF25-75) > 79% of predicted
- FVC greater than 80% of predicted
- Must be able to give informed consent for self.
Exclusion Criteria:
- Pregnant or breastfeeding females.
- Body Mass Index (BMI) greater than 32.
- Weight of greater than 220 pounds (100 kg).
- Allergies to shell fish, seafood, eggs or iodine.
- Heart disease, kidney disease or diabetes.
- Diagnosis of asthma.
- Usage of any medications that are known to affect the heart or lungs (contraceptives, anti-depressants, analgesics EXCEPT aspirin, antihypertensives, and medications for osteoporosis and gastrointestinal diseases will be allowed).
- Any metal in or on the body between the nose and the abdomen.
- Any major organ system disease (by judgment of study medical team).
For the subjects that will receive Sildenafil as part of the study, additional exclusion criteria are as follows:
- Nitroglycerin usage.
- Prior history of hypersensitivity to Sildenafil.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nonsusceptible Smokers (NS)
8 subjects recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT to assess perfused blood volume.
For the intervention, the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
|
One dose of 20 mg Sildenafil will be given one hour before CT imaging.
Other Names:
|
|
Experimental: Susceptible Smokers (SS)
11 subjects recruited to study non-contrast imaging at TLC and 20% VC and with contrast using DECT to assess pefused blood volume.
For the intervention the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
|
One dose of 20 mg Sildenafil will be given one hour before CT imaging.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perfused Blood Volume Assessed for a Change in Lung Inflammation Pre and Post Dose Sildenafil Administration
Time Frame: Change of perfused blood volume from baseline at one hour after sildenafil administration.
|
Perfused blood volume will be measured by CT scan at two time points and compared at two points, pre and post the administration of sildenafil.
|
Change of perfused blood volume from baseline at one hour after sildenafil administration.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Eric A Hoffman, University of Iowa
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Emphysema
- Emphysema
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Sildenafil Citrate
Other Study ID Numbers
Other Study ID Numbers
- 201101707
- 5R01HL112986 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Study Data/Documents
-
Individual Participant Data Set
Information identifier: Data Distribution
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.